Treatment of Diabetic Nephropathy with Chronic Kidney Disease After Acute Coronary Syndrome or PCI

Patients with diabetic nephropathy who also have chronic kidney disease and a recent acute coronary syndrome or percutaneous coronary intervention present a high-risk clinical combination that requires a structured antiplatelet management approach.

Clinical Scenario

Type 1 or type 2 diabetes mellitus with chronic kidney disease, in the setting of a recent acute coronary syndrome or percutaneous coronary intervention (PCI). The coexistence of impaired renal function and active cardiovascular risk shapes the antiplatelet strategy and requires careful multidisciplinary benefit-risk assessment.

Treatment Approach

Management centres on antiplatelet therapy, with the specific regimen and its duration determined by a multidisciplinary team weighing each patient's individual benefit-risk profile. Agent selection, sequencing, and transition criteria are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.nefro.2024.11.002

Dual antiplatelet therapy (with low-dose aspirin and a P2Y12 inhibitor) is recommended after acute coronary syndrome or percutaneous coronary intervention, followed by single antiplatelet therapy with a duration determined by a multidisciplinary team based on the benefit-risk profile.

View source ↗